Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer
Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer have?
Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer has 36 citations in the OpenAlex counts ScholarIQ stores.
When was Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer published?
Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer has 2022 year in the ScholarIQ index.
What is the open-access status of Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer?
Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer has hybrid oa status in the ScholarIQ index.
What is the DOI of Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer?
The DOI for Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer is on the source record.
What is the PMID of Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer?
The PMID for Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer is on the source record.
What is the OpenAlex record for Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer?
The OpenAlex for Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer is on the source record.